First Time Loading...

Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 0.75 USD -5.43% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. [ Read More ]

The intrinsic value of one ALGS stock under the Base Case scenario is 1.51 USD. Compared to the current market price of 0.75 USD, Aligos Therapeutics Inc is Undervalued by 50%.

Key Points:
ALGS Intrinsic Value
Base Case
1.51 USD
Undervaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Aligos Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ALGS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Aligos Therapeutics Inc

Provide an overview of the primary business activities
of Aligos Therapeutics Inc.

What unique competitive advantages
does Aligos Therapeutics Inc hold over its rivals?

What risks and challenges
does Aligos Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Aligos Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aligos Therapeutics Inc.

Provide P/S
for Aligos Therapeutics Inc.

Provide P/E
for Aligos Therapeutics Inc.

Provide P/OCF
for Aligos Therapeutics Inc.

Provide P/FCFE
for Aligos Therapeutics Inc.

Provide P/B
for Aligos Therapeutics Inc.

Provide EV/S
for Aligos Therapeutics Inc.

Provide EV/GP
for Aligos Therapeutics Inc.

Provide EV/EBITDA
for Aligos Therapeutics Inc.

Provide EV/EBIT
for Aligos Therapeutics Inc.

Provide EV/OCF
for Aligos Therapeutics Inc.

Provide EV/FCFF
for Aligos Therapeutics Inc.

Provide EV/IC
for Aligos Therapeutics Inc.

Show me price targets
for Aligos Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Aligos Therapeutics Inc?

How accurate were the past Revenue estimates
for Aligos Therapeutics Inc?

What are the Net Income projections
for Aligos Therapeutics Inc?

How accurate were the past Net Income estimates
for Aligos Therapeutics Inc?

What are the EPS projections
for Aligos Therapeutics Inc?

How accurate were the past EPS estimates
for Aligos Therapeutics Inc?

What are the EBIT projections
for Aligos Therapeutics Inc?

How accurate were the past EBIT estimates
for Aligos Therapeutics Inc?

Compare the revenue forecasts
for Aligos Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aligos Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aligos Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aligos Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Aligos Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aligos Therapeutics Inc with its peers.

Analyze the financial leverage
of Aligos Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Aligos Therapeutics Inc.

Provide ROE
for Aligos Therapeutics Inc.

Provide ROA
for Aligos Therapeutics Inc.

Provide ROIC
for Aligos Therapeutics Inc.

Provide ROCE
for Aligos Therapeutics Inc.

Provide Gross Margin
for Aligos Therapeutics Inc.

Provide Operating Margin
for Aligos Therapeutics Inc.

Provide Net Margin
for Aligos Therapeutics Inc.

Provide FCF Margin
for Aligos Therapeutics Inc.

Show all solvency ratios
for Aligos Therapeutics Inc.

Provide D/E Ratio
for Aligos Therapeutics Inc.

Provide D/A Ratio
for Aligos Therapeutics Inc.

Provide Interest Coverage Ratio
for Aligos Therapeutics Inc.

Provide Altman Z-Score Ratio
for Aligos Therapeutics Inc.

Provide Quick Ratio
for Aligos Therapeutics Inc.

Provide Current Ratio
for Aligos Therapeutics Inc.

Provide Cash Ratio
for Aligos Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Aligos Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Aligos Therapeutics Inc?

What is the current Free Cash Flow
of Aligos Therapeutics Inc?

Financials

Balance Sheet Decomposition
Aligos Therapeutics Inc

Current Assets 141.1m
Cash & Short-Term Investments 135.7m
Other Current Assets 5.4m
Non-Current Assets 10.4m
PP&E 9.8m
Other Non-Current Assets 625k
Current Liabilities 23.9m
Accounts Payable 2.5m
Accrued Liabilities 17m
Other Current Liabilities 4.3m
Non-Current Liabilities 35.5m
Long-Term Debt 231k
Other Non-Current Liabilities 35.3m
Efficiency

Earnings Waterfall
Aligos Therapeutics Inc

Revenue
15.5m USD
Operating Expenses
-103.7m USD
Operating Income
-88.1m USD
Other Expenses
448k USD
Net Income
-87.7m USD

Free Cash Flow Analysis
Aligos Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ALGS Profitability Score
Profitability Due Diligence

Aligos Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

16/100
Profitability
Score

Aligos Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

ALGS Solvency Score
Solvency Due Diligence

Aligos Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
64/100
Solvency
Score

Aligos Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALGS Price Targets Summary
Aligos Therapeutics Inc

Wall Street analysts forecast ALGS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALGS is 4.08 USD with a low forecast of 1.01 USD and a high forecast of 7.35 USD.

Lowest
Price Target
1.01 USD
35% Upside
Average
Price Target
4.08 USD
444% Upside
Highest
Price Target
7.35 USD
880% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ALGS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ALGS Price
Aligos Therapeutics Inc

1M 1M
-21%
6M 6M
-1%
1Y 1Y
-32%
3Y 3Y
-97%
5Y 5Y
-95%
10Y 10Y
-95%
Annual Price Range
0.75
52w Low
0.5601
52w High
1.36
Price Metrics
Average Annual Return -22.45%
Standard Deviation of Annual Returns 90.41%
Max Drawdown -98%
Shares Statistics
Market Capitalization 56.8m USD
Shares Outstanding 75 670 000
Percentage of Shares Shorted 1.27%

ALGS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

56.8m USD

Dividend Yield

0%

Description

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-10-16. The firm is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. The company uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. The company is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). The company developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The firm's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

Contact

CALIFORNIA
South San Francisco
One Corporate Dr., 2Nd Floor, 2nd Floor
+18004666059.0
https://www.aligos.com/

IPO

2020-10-16

Employees

93

Officers

CEO, President & Chairman of the Board
Dr. Lawrence M. Blatt MBA, Ph.D.
Executive VP & Chief Scientific Officer
Dr. Julian A. Symons DPHIL
Executive VP & CFO
Ms. Lesley Ann Calhoun CPA
VP and Head of People & Culture
Kristina Engeseth
Executive VP & Chief Medical Officer
Dr. Matthew W. McClure M.D.
Executive Vice President of Translational Safety Sciences
Dr. Sushmita M. Chanda DABT, Ph.D.
Show More
Executive VP & Head of Chemical Operations
Dr. David B. Smith Ph.D.
VP of Early Compound Development & Belgian Site Head
Dr. Tse-I Lin Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ALGS stock?

The intrinsic value of one ALGS stock under the Base Case scenario is 1.51 USD.

Is ALGS stock undervalued or overvalued?

Compared to the current market price of 0.75 USD, Aligos Therapeutics Inc is Undervalued by 50%.